Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 InterMune Sells Actimmune Rights | Contract Pharma

What are you searching for?

Sign in
Breaking News

InterMune Sells Actimmune Rights

Vidara to pay $55 million in cash plus two years of royalty payments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune, Inc. has reached a definitive agreement to sell its Actimmune (interferon gamma-1b) rights to Vidara Therapeutics International Ltd. for $55 million in cash, plus two years of royalty payments. Vidara is part of an international specialty pharma group of companies with operations in Ireland and the U.S. The transaction is expected to close during 2Q12, subject to certain closing conditions.
 
Dan Welch, chairman, chief executive officer and president of InterMune, said, “Several years ago, we stopped investigating new uses for Actimmune and it became a tactical financial asset for InterMune. The divesture of Actimmune will provide additional capital for InterMune to continue to focus on and invest in the registration and commercialization of Esbriet (pirfenidone) in Europe and elsewhere and to continue to advance our R&D programs. The cash infusion from this transaction combined with $377.2 million of existing cash and cash equivalents at the end of 1Q12 will provide additional financial resources to execute our Vision 2015 strategic plan.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters